Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats.

B. P. Kreft, A. Tanimoto, D. D. Stark, Y. Baba, L. Zhao, J. T. Chen, Carolyn Compton, J. P. Finn, F. M. Cavagna

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The efficacy for tumor detection of the hepatocyte-specific contrast agent gadobenate dimeglumine (gadolinium-BOPTA/Dimeg) was evaluated in four different experimental tumor models in rats. Histologic findings were correlated with quantitative data derived from ex vivo relaxometry and in vivo magnetic resonance (MR) imaging. Noninfiltrating tumors showed maximal enhancement of liver parenchyma 5-10 minutes after contrast agent administration, with a plateau over the next 30 minutes. In contrast, infiltrating tumors, which caused hepatocellular injury and inflammatory changes, delayed maximal enhancement of tumor-free parenchyma by 15-20 minutes. Nonspecific tumor enhancement depended on tumor vascularity and occurred in the early phase after contrast agent administration. Despite differences in specific enhancement of tumor-free parenchyma and nonspecific tumor enhancement, tumor-liver contrast-to-noise ratios increased 96%-248% in all tumor models 30 minutes after intravenous administration of 75 mmol/kg Gd-BOPTA/Dimeg. Gd-BOPTA/Dimeg enhanced tumor conspicuity independently of the histologic characteristics of the tumor.

Original languageEnglish (US)
Pages (from-to)41-49
Number of pages9
JournalJournal of magnetic resonance imaging : JMRI
Volume3
Issue number1
StatePublished - Jan 1993
Externally publishedYes

Fingerprint

Noise
Magnetic Resonance Imaging
Liver
Neoplasms
Contrast Media
gadobenic acid
Intravenous Administration
Hepatocytes
Theoretical Models

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Kreft, B. P., Tanimoto, A., Stark, D. D., Baba, Y., Zhao, L., Chen, J. T., ... Cavagna, F. M. (1993). Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats. Journal of magnetic resonance imaging : JMRI, 3(1), 41-49.

Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats. / Kreft, B. P.; Tanimoto, A.; Stark, D. D.; Baba, Y.; Zhao, L.; Chen, J. T.; Compton, Carolyn; Finn, J. P.; Cavagna, F. M.

In: Journal of magnetic resonance imaging : JMRI, Vol. 3, No. 1, 01.1993, p. 41-49.

Research output: Contribution to journalArticle

Kreft, BP, Tanimoto, A, Stark, DD, Baba, Y, Zhao, L, Chen, JT, Compton, C, Finn, JP & Cavagna, FM 1993, 'Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats.', Journal of magnetic resonance imaging : JMRI, vol. 3, no. 1, pp. 41-49.
Kreft, B. P. ; Tanimoto, A. ; Stark, D. D. ; Baba, Y. ; Zhao, L. ; Chen, J. T. ; Compton, Carolyn ; Finn, J. P. ; Cavagna, F. M. / Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats. In: Journal of magnetic resonance imaging : JMRI. 1993 ; Vol. 3, No. 1. pp. 41-49.
@article{7396d69ef6594380b4cecde3d7a9bc20,
title = "Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats.",
abstract = "The efficacy for tumor detection of the hepatocyte-specific contrast agent gadobenate dimeglumine (gadolinium-BOPTA/Dimeg) was evaluated in four different experimental tumor models in rats. Histologic findings were correlated with quantitative data derived from ex vivo relaxometry and in vivo magnetic resonance (MR) imaging. Noninfiltrating tumors showed maximal enhancement of liver parenchyma 5-10 minutes after contrast agent administration, with a plateau over the next 30 minutes. In contrast, infiltrating tumors, which caused hepatocellular injury and inflammatory changes, delayed maximal enhancement of tumor-free parenchyma by 15-20 minutes. Nonspecific tumor enhancement depended on tumor vascularity and occurred in the early phase after contrast agent administration. Despite differences in specific enhancement of tumor-free parenchyma and nonspecific tumor enhancement, tumor-liver contrast-to-noise ratios increased 96{\%}-248{\%} in all tumor models 30 minutes after intravenous administration of 75 mmol/kg Gd-BOPTA/Dimeg. Gd-BOPTA/Dimeg enhanced tumor conspicuity independently of the histologic characteristics of the tumor.",
author = "Kreft, {B. P.} and A. Tanimoto and Stark, {D. D.} and Y. Baba and L. Zhao and Chen, {J. T.} and Carolyn Compton and Finn, {J. P.} and Cavagna, {F. M.}",
year = "1993",
month = "1",
language = "English (US)",
volume = "3",
pages = "41--49",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats.

AU - Kreft, B. P.

AU - Tanimoto, A.

AU - Stark, D. D.

AU - Baba, Y.

AU - Zhao, L.

AU - Chen, J. T.

AU - Compton, Carolyn

AU - Finn, J. P.

AU - Cavagna, F. M.

PY - 1993/1

Y1 - 1993/1

N2 - The efficacy for tumor detection of the hepatocyte-specific contrast agent gadobenate dimeglumine (gadolinium-BOPTA/Dimeg) was evaluated in four different experimental tumor models in rats. Histologic findings were correlated with quantitative data derived from ex vivo relaxometry and in vivo magnetic resonance (MR) imaging. Noninfiltrating tumors showed maximal enhancement of liver parenchyma 5-10 minutes after contrast agent administration, with a plateau over the next 30 minutes. In contrast, infiltrating tumors, which caused hepatocellular injury and inflammatory changes, delayed maximal enhancement of tumor-free parenchyma by 15-20 minutes. Nonspecific tumor enhancement depended on tumor vascularity and occurred in the early phase after contrast agent administration. Despite differences in specific enhancement of tumor-free parenchyma and nonspecific tumor enhancement, tumor-liver contrast-to-noise ratios increased 96%-248% in all tumor models 30 minutes after intravenous administration of 75 mmol/kg Gd-BOPTA/Dimeg. Gd-BOPTA/Dimeg enhanced tumor conspicuity independently of the histologic characteristics of the tumor.

AB - The efficacy for tumor detection of the hepatocyte-specific contrast agent gadobenate dimeglumine (gadolinium-BOPTA/Dimeg) was evaluated in four different experimental tumor models in rats. Histologic findings were correlated with quantitative data derived from ex vivo relaxometry and in vivo magnetic resonance (MR) imaging. Noninfiltrating tumors showed maximal enhancement of liver parenchyma 5-10 minutes after contrast agent administration, with a plateau over the next 30 minutes. In contrast, infiltrating tumors, which caused hepatocellular injury and inflammatory changes, delayed maximal enhancement of tumor-free parenchyma by 15-20 minutes. Nonspecific tumor enhancement depended on tumor vascularity and occurred in the early phase after contrast agent administration. Despite differences in specific enhancement of tumor-free parenchyma and nonspecific tumor enhancement, tumor-liver contrast-to-noise ratios increased 96%-248% in all tumor models 30 minutes after intravenous administration of 75 mmol/kg Gd-BOPTA/Dimeg. Gd-BOPTA/Dimeg enhanced tumor conspicuity independently of the histologic characteristics of the tumor.

UR - http://www.scopus.com/inward/record.url?scp=0027345663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027345663&partnerID=8YFLogxK

M3 - Article

C2 - 8428100

AN - SCOPUS:0027345663

VL - 3

SP - 41

EP - 49

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 1

ER -